Vistagen Therapeutics (VTGN) Stock Price, News & Analysis

Company Overview

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $2.86 to $2.96
• 50-Day Range: $2.49 to $3.01
• 52-Week Range: $2.22 to $5.74
• Volume: 86,295 shs
• Average Volume: 185,657 shs
• Market Capitalization: $81.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Vistagen Therapeutics Stock Analysis - MarketRank™

Vistagen Therapeutics scored higher than 17% of companies evaluated by MarketBeat, and ranked 835th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Vistagen Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vistagen Therapeutics are expected to grow in the coming year, from ($1.77) to ($1.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vistagen Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vistagen Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vistagen Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.50% of the float of Vistagen Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vistagen Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vistagen Therapeutics has recently decreased by 2.90%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vistagen Therapeutics does not currently pay a dividend.

Dividend Growth

Vistagen Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.50% of the float of Vistagen Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vistagen Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vistagen Therapeutics has recently decreased by 2.90%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: -0.74

News Sentiment

Vistagen Therapeutics has a news sentiment score of -0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Vistagen Therapeutics this week, compared to 1 article on an average week.

Search Interest

4 people have searched for VTGN on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vistagen Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.29% of the stock of Vistagen Therapeutics is held by insiders.

Percentage Held by Institutions

78.39% of the stock of Vistagen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VTGN Stock Analysis - Frequently Asked Questions

How have VTGN shares performed this year?

Vistagen Therapeutics' stock was trading at $2.95 at the beginning of the year. Since then, VTGN shares have decreased by 4.1% and is now trading at $2.83.
View the best growth stocks for 2025 here.

How were Vistagen Therapeutics' earnings last quarter?

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) posted its earnings results on Thursday, February, 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.02. The business had revenue of $230 billion for the quarter, compared to the consensus estimate of $0.18 million. Vistagen Therapeutics had a negative net margin of 6,777.08% and a negative trailing twelve-month return on equity of 48.12%.

When did Vistagen Therapeutics' stock split?

Vistagen Therapeutics's stock reverse split on the morning of Wednesday, June 7th 2023. The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Vistagen Therapeutics' major shareholders?

Vistagen Therapeutics' top institutional shareholders include Stempoint Capital LP (8.36%), Nantahala Capital Management LLC (7.12%), JPMorgan Chase & Co. (2.77%) and Almitas Capital LLC (0.91%). Insiders that own company stock include Commodore Capital Lp, Venrock Healthcare Capital Par, Shawn Singh, Reid G Adler and Jerry B Gin.
View institutional ownership trends.

How do I buy shares of Vistagen Therapeutics?

Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vistagen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vistagen Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 2/13/2025
• Today: 3/25/2025
• Fiscal Year End: 3/31/2025
• Next Earnings (Estimated): 6/10/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VTGN
• CIK: 1411685
• Web: www.vistagen.com
• Phone: (650) 577-3600
• Fax: 888-482-2602
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,360,000.00
• Net Margins: -6,777.08%
• Pretax Margin: -6,775.93%
• Return on Equity: -48.12%
• Return on Assets: -43.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.35
• Quick Ratio: 9.35

Sales & Book Value

• Annual Sales: $698,000.00
• Price / Sales: 117.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.81 per share
• Price / Book: 1.01

Miscellaneous

• Outstanding Shares: 28,862,000
• Free Float: 28,490,000
• Market Cap: $81.68 million
• Optionable: Optionable
• Beta: 0.62